Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

NCT01446159 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01446159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01446159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2011
Completion date
June 28, 2019
Enrollment
188 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-sensitive, her-2 negative metastatic breast cancer